Literature DB >> 16272152

Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants.

L Keith Henry1, Julie R Field, Erika M Adkins, M Laura Parnas, Roxanne A Vaughan, Mu-Fa Zou, Amy H Newman, Randy D Blakely.   

Abstract

In previous studies examining the structural determinants of antidepressant and substrate recognition by serotonin transporters (SERTs), we identified Tyr-95 in transmembrane segment 1 (TM1) of human SERT as a major determinant of binding for several antagonists, including racemic citalopram ((RS)-CIT). Here we described a separate site in hSERT TM3 (Ile-172) that impacts (RS)-CIT recognition when switched to the corresponding Drosophila SERT residue (I172M). The hSERT I172M mutant displays a marked loss of inhibitor potency for multiple inhibitors such as (RS)-CIT, clomipramine, RTI-55, fluoxetine, cocaine, nisoxetine, mazindol, and nomifensine, whereas recognition of substrates, including serotonin and 3,4-methylenedioxymethamphetamine, is unaffected. Selectivity for antagonist interactions is evident with this substitution because the potencies of the antidepressants tianeptine and paroxetine are unchanged. Reduced cocaine analog recognition was verified in photoaffinity labeling studies using [(125)I]MFZ 2-24. In contrast to the I172M substitution, other substitutions at this position significantly affected substrate recognition and/or transport activity. Additionally, the mouse mutation (mSERT I172M) exhibits similar selective changes in inhibitor potency. Unlike hSERT or mSERT, analogous substitutions in mouse dopamine transporter (V152M) or human norepinephrine transporter (V148M) result in transporters that bind substrate but are deficient in the subsequent translocation of the substrate. A double mutant hSERT Y95F/I172M had a synergistic impact on (RS)-CIT recognition ( approximately 10,000-fold decrease in (RS)-CIT potency) in the context of normal serotonin recognition. The less active enantiomer (R)-CIT responded to the I172M substitution like (S)-CIT but was relatively insensitive to the Y95F substitution and did not display a synergistic loss at Y95F/I172M. An hSERT mutant with single cysteine substitutions in TM1 and TM3 resulted in formation of a high affinity cadmium metal coordination site, suggesting proximity of these domains in the tertiary structure of SERT. These studies provided evidence for distinct binding sites coordinating SERT antagonists and revealed a close interaction between TM1 and TM3 differentially targeted by stereoisomers of CIT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272152     DOI: 10.1074/jbc.M505055200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  77 in total

1.  Molecular mechanism of serotonin transporter inhibition elucidated by a new flexible docking protocol.

Authors:  Mari Gabrielsen; Rafał Kurczab; Aina W Ravna; Irina Kufareva; Ruben Abagyan; Zdzisław Chilmonczyk; Andrzej J Bojarski; Ingebrigt Sylte
Journal:  Eur J Med Chem       Date:  2011-10-20       Impact factor: 6.514

Review 2.  The solute carrier 6 family of transporters.

Authors:  Stefan Bröer; Ulrik Gether
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 3.  Substrate and drug binding sites in LeuT.

Authors:  Ajeeta Nyola; Nathan K Karpowich; Juan Zhen; Jennifer Marden; Maarten E Reith; Da-Neng Wang
Journal:  Curr Opin Struct Biol       Date:  2010-06-16       Impact factor: 6.809

4.  Synthesis, in vitro binding studies and docking of long-chain arylpiperazine nitroquipazine analogues, as potential serotonin transporter inhibitors.

Authors:  Małgorzata Jarończyk; Karol Wołosewicz; Mari Gabrielsen; Gabriel Nowak; Irina Kufareva; Aleksander P Mazurek; Aina W Ravna; Ruben Abagyan; Andrzej J Bojarski; Ingebrigt Sylte; Zdzisław Chilmonczyk
Journal:  Eur J Med Chem       Date:  2012-01-15       Impact factor: 6.514

Review 5.  Y95 and E444 interaction required for high-affinity S-citalopram binding in the human serotonin transporter.

Authors:  Steven Combs; Kristian Kaufmann; Julie R Field; Randy D Blakely; Jens Meiler
Journal:  ACS Chem Neurosci       Date:  2010-10-27       Impact factor: 4.418

6.  Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter.

Authors:  Brent J Thompson; Tammy Jessen; L K Henry; Julie R Field; Karen L Gamble; Paul J Gresch; Ana M Carneiro; Rebecca E Horton; Peter J Chisnell; Yekaterina Belova; Douglas G McMahon; Lynette C Daws; Randy D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

7.  Functional coding variation in recombinant inbred mouse lines reveals multiple serotonin transporter-associated phenotypes.

Authors:  Ana M D Carneiro; David C Airey; Brent Thompson; Chong-Bin Zhu; Lu Lu; Elissa J Chesler; Keith M Erikson; Randy D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

8.  Structure and localisation of drug binding sites on neurotransmitter transporters.

Authors:  Aina W Ravna; Ingebrigt Sylte; Svein G Dahl
Journal:  J Mol Model       Date:  2009-02-24       Impact factor: 1.810

9.  A competitive inhibitor traps LeuT in an open-to-out conformation.

Authors:  Satinder K Singh; Chayne L Piscitelli; Atsuko Yamashita; Eric Gouaux
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

10.  The binding sites for cocaine and dopamine in the dopamine transporter overlap.

Authors:  Thijs Beuming; Julie Kniazeff; Marianne L Bergmann; Lei Shi; Luis Gracia; Klaudia Raniszewska; Amy Hauck Newman; Jonathan A Javitch; Harel Weinstein; Ulrik Gether; Claus J Loland
Journal:  Nat Neurosci       Date:  2008-06-22       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.